Grail, Inc.
Clinical trials sponsored by Grail, Inc., explained in plain language.
A healthcare company developing early cancer detection tests, subsidiary of Illumina.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Blood test could spot hidden cancers early in thousands
Diagnosis OngoingThis trial is testing a new blood test, called Galleri, that looks for signs of many different cancers. The goal is to see if adding this test to standard NHS screening helps find cancers at an early stage, when treatment is more likely to work. About 140,000 people aged 50-77 in…
Phase: NA • Sponsor: GRAIL, Inc. • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
Simple blood test could spot hidden cancers before symptoms start
Diagnosis OngoingThis study is testing a new blood test that can detect many types of cancer early, even before symptoms appear. About 35,000 adults aged 50 and older will take the test, and if it finds a possible cancer signal, they will get follow-up exams to confirm. The goal is to see how wel…
Phase: NA • Sponsor: GRAIL, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
14,000 people help test new blood test for early cancer detection
Knowledge-focused OngoingThis study is tracking about 14,000 adults who chose to take the Galleri® blood test, which looks for many types of cancer early. Researchers want to see how well the test works in real doctor's offices and how patients feel about it. The goal is to learn more about using this te…
Sponsor: GRAIL, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC